T cell clones specific for p21 ras-derived peptides: characterization of their fine specificity and HLA restriction
- PMID: 8449222
- DOI: 10.1002/eji.1830230328
T cell clones specific for p21 ras-derived peptides: characterization of their fine specificity and HLA restriction
Abstract
Peptides corresponding to the mutated regions of the oncoprotein p21 ras are immunogenic and capable of eliciting HLA class II-restricted T cell responses. Here we report studies on the fine specificity of four T lymphocyte clones (TLC) from a single donor, using various truncated peptides derived from the residues 6-19 of p21 ras and a panel of well-characterized HLA homozygous cells as antigen-presenting cells. Putative minimum peptides of nine or ten amino acids could be defined for each TLC. Two of the TLC recognized peptides presented by DR2, and the two others recognized peptides presented by DQ6. Some notable differences in the requirement for certain amino acids were seen between the DR- and DQ-restricted TLC. Thus, Ser at residue 17 was required for stimulation of the DQ6-but not the DR2-restricted TLC. Val at residue 8 was essential for stimulation of all TLC, whereas one of the DR2-restricted TLC also required Val at residue 7. Some peptides which were nonstimulatory were still capable of binding to DQ6 molecules in peptide competition experiments. The results may be of importance for potential immunotherapy of cancer where transforming ras oncoproteins are involved.
Similar articles
-
T cell epitopes encompassing the mutational hot spot position 61 of p21 ras. Promiscuity in ras peptide binding to HLA.Eur J Immunol. 1994 Feb;24(2):410-4. doi: 10.1002/eji.1830240221. Eur J Immunol. 1994. PMID: 7507844
-
Overlapping epitopes encompassing a point mutation (12 Gly-->Arg) in p21 ras can be recognized by HLA-DR, -DP and -DQ restricted T cells.Eur J Immunol. 1993 Oct;23(10):2687-91. doi: 10.1002/eji.1830231045. Eur J Immunol. 1993. PMID: 7691613
-
T-cell responses against products of oncogenes: generation and characterization of human T-cell clones specific for p21 ras-derived synthetic peptides.Hum Immunol. 1992 Apr;33(4):266-74. doi: 10.1016/0198-8859(92)90334-j. Hum Immunol. 1992. PMID: 1639630
-
T cell recognition of transforming proteins encoded by mutated ras proto-oncogenes.J Immunol. 1991 Mar 15;146(6):2059-65. J Immunol. 1991. PMID: 2005390
-
Clonal sketches of the immune response.EMBO J. 1988 Oct;7(10):2945-51. doi: 10.1002/j.1460-2075.1988.tb03156.x. EMBO J. 1988. PMID: 3053159 Free PMC article. Review. No abstract available.
Cited by
-
The role of the immune system in anti-tumour responses. Potential for drug therapy.Drugs Aging. 1995 Oct;7(4):266-77. doi: 10.2165/00002512-199507040-00002. Drugs Aging. 1995. PMID: 8535054 Review.
-
Tumor cells engineered to produce cytokines or cofactors as cellular vaccines: do animal studies really support clinical trials?Cancer Immunol Immunother. 1995 Nov;41(5):265-70. doi: 10.1007/BF01517213. Cancer Immunol Immunother. 1995. PMID: 8536271 Free PMC article. Review. No abstract available.
-
Colorectal cancer vaccines: Tumor-associated antigens vs neoantigens.World J Gastroenterol. 2018 Dec 28;24(48):5418-5432. doi: 10.3748/wjg.v24.i48.5418. World J Gastroenterol. 2018. PMID: 30622371 Free PMC article. Review.
-
Pilot study of mutant ras peptide-based vaccine as an adjuvant treatment in pancreatic and colorectal cancers.Cancer Immunol Immunother. 2008 Sep;57(9):1413-20. doi: 10.1007/s00262-008-0477-6. Epub 2008 Feb 23. Cancer Immunol Immunother. 2008. PMID: 18297281 Free PMC article. Clinical Trial.
-
Characterisation of immune responses in pancreatic carcinoma patients after mutant p21 ras peptide vaccination.Br J Cancer. 1996 Dec;74(11):1828-33. doi: 10.1038/bjc.1996.638. Br J Cancer. 1996. PMID: 8956801 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous